A minireview of CYP2C9 and CYP2C19 single nucleotide polymorphisms (SNPs) among Malaysian populations

Rasmaizatul Akma Rosdi, Narazah Mohd Yusoff, Rusli Ismail, Tan Soo Choon, Nurfadhlina Musa, Surini Yusoff

Abstract


It has been recognized extensively that studies of pharmacogenetics provide massive examples of causal relationship between genotypes and drug effectiveness to account for interindividual phenotypic variations in drug therapy. In most cases, cytochrome P450 (CYP) polymorphisms are one of the major variables that affecting those drug plasma concentration, drug detoxification and drug activation in humans. Thus, understanding of CYP polymorphisms can be crucially valuable in order to allow early and more accurate drug dosage prediction and improve the drug response accordingly. Despite the high level of homologous amino acid sequences, CYP2C9 and CYP2C19 genes are among the most important CYP genes which metabolize a wide range of clinically therapeutic drugs. Several critical reviews have been published relating to the aforementioned genes. However, this minireview aims to systematically merge reported studies on the SNPs frequencies of both genes concentrating only on Malaysian population. It is hoped that, the minireview can be an opener for new opportunities to reevaluate the evidence on the prevalence of CYP2C genes as a potential genetic factor influencing a particular drug efficacy and safety among Malaysian. Such evaluation can be developed to the next level of early prediction of better and specific drug treatment, thereby improving the drug response while helping the government in minimising the drug expenditures.

Keywords


pharmacogenetics, cytochrome P450, CYP2C9 gene, CYP2C19 gene, Malaysian population, allele frequency, personalized medicine

Full Text:

PDF

References


Ishikawa T, Tsuji A, Inui K, Sai Y, Anzai N, et al. The genetic polymorphism of drug transporters: functional analysis approaches. Pharmacogenomics. 2004; 5(1):pp.67-99.

De Montellano O. Cytochrome P450: Structure, Mechanism and Biochemistry. New York; Springer, 2005.

Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther. 2007; 116:pp.496-526.

Wolf CR, Smith G. Pharmacogenetics. Br Med Bull. 1999; 55(2):pp.366-386.

Danielson PB. The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. Curr Drug Metab. 2002; 3:pp.561-597.

Demorais SM, Schweikl H, Blaisdell J, Goldstein JA. Gene structure and upstream regulatory regions of human CYP2C9 and CYP2C18. Biochem Biophys Res Commun. 1993; 194:pp.194-201.

Yang X, Zhang B, Molony C, Chudin E, Hao K, et al. Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver. Genome Res. 2010; 20:pp.1020-1036.

Goldstein JA, de Morais SM. Biochemistry and molecular biology of the human CYP2C family. Pharmacogenetics. 1994; 4(6):pp.285-299.

Romkes M, Faletto MB, Blaisdell JA, Goldstein J. Cloning and Expression of Complementary DNAs for Multiple Members of the Human Cytochrome P450IIC Subfamily. 1991.

Daly AK. Pharmacogenetics of the major polymorphic metabolizing enzymes. Fundam Clin Pharmacol. 2003; 17:pp.27-41.

Gerbal-Chaloin S, Daujat M, Pascussi JM, Pichard-Garcia L, Vilarem MJ, et al. Transcriptional regulation of CYP2C9 gene. Role of glucocorticoid receptor and constitutive androstane receptor. J Biol Chem. 2002; 277:pp.209-217.

Miners JO, Birkett DJ. Cytochrome P4502C9: An enzyme of major importance in human drug metabolism. Br J Clin Pharmacol. 1998; 45(6):pp.525-538.

Lim JSL, Chen XA, Singh O, Yap YS, Ng RCH, et al. Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients. Br J Clin Pharmacol. 2011; 71(5):pp.737-750.

Zainuddin Z, Teh LK, Suhaimi AWM, Ismail R. Malaysian Indians are genetically similar to Caucasians : CYP2C9 polymorphism. J Clin Pharm Ther. 2006; 31:pp.187-191.

Seng KC, Gin GG, Sangkar JV, Phipps ME. Frequency of cytochrome P450 2C9 (CYP2C9) alleles in three ethnic groups in Malaysia. Asian Pacific J Mol Biol Biotechnol. 2003; 11(2):pp.83-91.

Yang JQ, Morin S, Verstuyft C, Fan LA, Zhang Y, et al. Frequency of cytochrome P450 2C9 allelic variants in the Chinese and French populations. Fundam Clin Pharmacol. 2003; 17:pp.373-376.

Yoon Y-R, Shon J-H, Kim M-K, Lim Y-C, Lee H-R, et al. Frequency of cytochrome P450 2C9 mutant alleles in a Korean population. Br J Clin Pharmacol. 2001; 51:pp.277-280.

Miyuki K, Ichiro I, Kohsuke M, Akinori U, Shun H. Genetic polymorphisms of cytochrome P450s, CYP2C19 and CYP2C9 in a Japanese population. Ther Drug Monit. 1998; 20(3):pp.243-247.

Rosdi R, Mohd Yusoff N, Ismail R, Choon T, Saleem M, et al. High allele frequency of CYP2C9*3 (rs1057910) in a Negrito’s subtribe population in Malaysia; Aboriginal people of Jahai. Ann Hum Biol. 2015.

Imai J, Ieiri I, Mamiya K, Miyahara S, Furuumi H, et al. Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients : genetic analysis of the CYP2C9 locus. Pharmacogenetics. 2000; 10:pp.85-89.

Saab YB, Langaee T. Genetic polymorphisms of CYP2C9: Comparison of prevalence in the Lebanese population with other populations. Pharmacol Pharm. 2011; 2:pp.88-93.

Dickmann LJ, Rettie AE, Kneller MB, Kim RB, Wood AJJ, et al. Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol Pharmacol. 2001; 60(2):pp.382-387.

Xie H-G, Prasad HC, Kim RB, Stein CM. CYP2C9 allelic variants : ethnic distribution and functional significance. Adv Drug Deliv Rev. 2002; 54:pp.1257-1270.

Rendic S, Di Carlo F. Human cytochrome P450 enzymes: a status report summarizng their actions, substrates, inducers, and inhibitors. Drug Metab Rev. 1997; 29:pp.413-580.

Desta Z, Zhao X, Shin J-G, Flockhart DA. Clinical significance of the Cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet. 2002; 41(12):pp.913-958.

Ellis KJ, Stouffer GA, McLeod HL, Lee CR. Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations. Pharmacogenomics. 2009; 10(11):pp.1799-1817.

Sim SC, Risinger C, Dahl M-L, Aklillu E, Christensen M, et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther. 2006; 79(1):pp.103-113.

Hu L-M, Dai D-P, Hu G-X, Yang J-F, Xu R, et al. Genetic polymorphisms and novel allelic variants of CYP2C19 in the Chinese Han population. Pharmacogenomics. 2012; 13(14):pp.1571-1581.

Mejin M, Tiong WN, Lai LYH, Tiong LL, Bujang AM, et al. CYP2C19 genotypes and their impact on clopidogrel responsiveness in percutaneous coronary intervention. Int J Clin Pharm. 2013; 35(4):pp.621-628.

Sistonen J, Fuselli S, Palo JU, Chauhan N, Padh H, et al. Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales. Pharmacogenet Genomics. 2009; 19(2):pp.170-179.

Hitchen L. Adverse Drug Reactions Result in 250,000 UK Admissions a Year. Vol 332. 2006.




Copyright (c) 2017 Journal of Biomedical and Clinical Sciences (JBCS)



Journal of Biomedical and Clinical Sciences (JBCS) publishes original research articles, short review, short communication, case reports, quiz and letter to editor that covering the areas of fundamental aspects of biomedical and clinical sciences, from pre-clinical towards translational research and their applications in medicine, dentistry and healthcare management. JBCS aims to provide a platform for basic science and clinical researchers to communicate and share their research findings to the advancement of technologies in biomedical and clinical sciences by providing maximum access to scholarly communication.

Flag Counter           

                     

                                              Copyright © 2016 AMDI Publisher, Universiti Sains Malaysia.
Disclaimer : This website has been updated to the best of our knowledge to be accurate. However, Universiti Sains Malaysia shall not be liable for any loss or damage caused by the usage of any information obtained from this web site.
                                            Best viewed: Mozilla Firefox 4.0 & Google Chrome at 1024 × 768 resolution.